Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 2/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | NNMT | P40261 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3703416 | 0.91 | PDE4A (0.48) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25048716 | 0.91 | PDE4A (0.48) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL167849 | 0.86 | TRPV6 (0.46) | SLC6A2SLC6A4SLC6A3NNMTTRPV6 | |
| SCHEMBL22048068 | 0.83 | CHRNA7 (0.49) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16475195 | 0.83 | PDGFRB (0.44) | SLC6A2SLC6A4SLC6A3NNMTTRPV6 | |
| SCHEMBL16475192 | 0.83 | PDGFRB (0.47) | SLC6A2SLC6A4SLC6A3NNMTTRPV6 | |
| SCHEMBL25347011 | 0.82 | PDE4A (0.46) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL27211115 | 0.82 | PDE4A (0.46) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25342894 | 0.82 | PDE4A (0.46) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5182802 | 0.81 | KDM4E (0.50) | SLC6A2SLC6A4SLC6A3NNMTPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111712490-A | Amino-substituted pyridone derivatives, preparation method and medical application thereof | 上海海雁医药科技有限公司 | 2020-09-25 | — | — | CN | disclosed |
| WO-2020108579-A1 | AMINO-SUBSTITUTED PYRIDONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 上海海雁医药科技有限公司 | 2020-06-04 | — | — | WO | disclosed |
| EP-2580208-B1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-06 | — | — | EP | disclosed |
| US-8921559-B2 | 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-30 | — | — | US | disclosed |
| EP-2646429-B1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-15 | — | — | EP | disclosed |
| EP-2646429-A1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | Janssen Pharmaceutica, N.V. (BE) | 2013-10-09 | — | — | EP | disclosed |
| US-8436023-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-05-07 | — | — | US | disclosed |
| EP-2580208-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | Janssen Pharmaceutica, N.V. (BE) | 2013-04-17 | — | — | EP | disclosed |
| WO-2012075115-A1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142733-A1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-06-07 | — | — | US | disclosed |
| WO-2011156554-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-15 | — | — | WO | disclosed |
| US-20110306592-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306592-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | ESR2 582/4885PDE4A 1778/4885PDE4B 1817/4885 |
| US-20120142733-A1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | CCR2, CCR5, CCR1 | ESR2 810/4885PDE4A 388/4885PDE4B 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.